Written by AZoNanoNov 27 2003
|
|
An Israeli subsidiary to BioDelivery Sciences International Inc. (BDSI) is being created to develop nanoscale drug-delivery therapies to treat an inherited disease caused by an enzyme deficiency. Tentatively called Biorazyme Ltd., the company is co-owned by Newark, N.J. based BDSI and Israeli joint venture partners. It will develop a new oral enzyme replacement for Gaucher Disease. BDSI's Bioral delivery technology uses nanocrystalline delivery vehicles made from all-natural components that wrap around the enzyme and allow it to be delivered into the body. |
Posted 25th November 2003 |